These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

417 related articles for article (PubMed ID: 14962581)

  • 21. Solid state amorphization of pharmaceuticals.
    Willart JF; Descamps M
    Mol Pharm; 2008; 5(6):905-20. PubMed ID: 18954076
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Influence of copolymer composition on the phase behavior of solid dispersions.
    Prudic A; Kleetz T; Korf M; Ji Y; Sadowski G
    Mol Pharm; 2014 Nov; 11(11):4189-98. PubMed ID: 25295846
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Understanding the glass-forming ability of active pharmaceutical ingredients for designing supersaturating dosage forms.
    Kawakami K; Usui T; Hattori M
    J Pharm Sci; 2012 Sep; 101(9):3239-48. PubMed ID: 22531946
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Drug-excipient compatibility screening--role of thermoanalytical and spectroscopic techniques.
    Chadha R; Bhandari S
    J Pharm Biomed Anal; 2014 Jan; 87():82-97. PubMed ID: 23845418
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmaceutical co-crystals.
    Vishweshwar P; McMahon JA; Bis JA; Zaworotko MJ
    J Pharm Sci; 2006 Mar; 95(3):499-516. PubMed ID: 16444755
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Critical considerations for the qualitative and quantitative determination of process-induced disorder in crystalline solids.
    Newman A; Zografi G
    J Pharm Sci; 2014 Sep; 103(9):2595-2604. PubMed ID: 24623166
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of the crystalline and amorphous states of drug products by nanothermal analysis and Raman imaging.
    Nakamoto K; Urasaki T; Hondo S; Murahashi N; Yonemochi E; Terada K
    J Pharm Biomed Anal; 2013 Mar; 75():105-11. PubMed ID: 23246930
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Regulatory considerations of pharmaceutical solid polymorphism in Abbreviated New Drug Applications (ANDAs).
    Raw AS; Furness MS; Gill DS; Adams RC; Holcombe FO; Yu LX
    Adv Drug Deliv Rev; 2004 Feb; 56(3):397-414. PubMed ID: 14962589
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Insight to the thermodynamic stability of molecular crystals through crystallographic studies of a multipolymorph system.
    Ng AT; Lai C; Dabros M; Gao Q
    J Pharm Sci; 2014 Nov; 103(11):3423-3431. PubMed ID: 25252084
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A novel approach for analyzing glass-transition temperature vs. composition patterns: application to pharmaceutical compound+polymer systems.
    Kalogeras IM
    Eur J Pharm Sci; 2011 Apr; 42(5):470-83. PubMed ID: 21324354
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The contribution of Raman spectroscopy to the analysis of phase transformations in pharmaceutical compounds.
    Hédoux A; Guinet Y; Descamps M
    Int J Pharm; 2011 Sep; 417(1-2):17-31. PubMed ID: 21256937
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Physical stability of amorphous acetanilide derivatives improved by polymer excipients.
    Miyazaki T; Yoshioka S; Aso Y
    Chem Pharm Bull (Tokyo); 2006 Aug; 54(8):1207-10. PubMed ID: 16880672
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Local mobility in amorphous pharmaceuticals--characterization and implications on stability.
    Bhattacharya S; Suryanarayanan R
    J Pharm Sci; 2009 Sep; 98(9):2935-53. PubMed ID: 19499564
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-Term Amorphous Drug Stability Predictions Using Easily Calculated, Predicted, and Measured Parameters.
    Nurzyńska K; Booth J; Roberts CJ; McCabe J; Dryden I; Fischer PM
    Mol Pharm; 2015 Sep; 12(9):3389-98. PubMed ID: 26236939
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Crystallization pathways and kinetics of carbamazepine-nicotinamide cocrystals from the amorphous state by in situ thermomicroscopy, spectroscopy, and calorimetry studies.
    Seefeldt K; Miller J; Alvarez-Núñez F; Rodríguez-Hornedo N
    J Pharm Sci; 2007 May; 96(5):1147-58. PubMed ID: 17455346
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rational coformer or solvent selection for pharmaceutical cocrystallization or desolvation.
    Abramov YA; Loschen C; Klamt A
    J Pharm Sci; 2012 Oct; 101(10):3687-97. PubMed ID: 22821740
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Using terahertz pulsed spectroscopy to quantify pharmaceutical polymorphism and crystallinity.
    Strachan CJ; Taday PF; Newnham DA; Gordon KC; Zeitler JA; Pepper M; Rades T
    J Pharm Sci; 2005 Apr; 94(4):837-46. PubMed ID: 15736195
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Crystallization and solid state properties of molecules of pharmaceutical interest].
    Bauer M
    Ann Pharm Fr; 2002 May; 60(3):152-60. PubMed ID: 12050594
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Modeling and prediction of cocrystal phase diagrams.
    Ainouz A; Authelin JR; Billot P; Lieberman H
    Int J Pharm; 2009 Jun; 374(1-2):82-9. PubMed ID: 19446763
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Applications of solid-state NMR to pharmaceutical polymorphism and related matters.
    Harris RK
    J Pharm Pharmacol; 2007 Feb; 59(2):225-39. PubMed ID: 17270076
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.